At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst. Warren Buffett Sold Over $134 Billion Worth of Stock in 2024, But His Most Recent $200 Million in ...

NVO currently markets its obesity drug Wegovy and diabetes drug Ozempic, both of which contain the active ingredient semaglutide — a direct competitor to Lilly’s tirzepatide. Shares of Viking ...

We continued to make progress on our manufacturing build-out, and U.S. supply across all doses of tirzepatide was available throughout Q4," said Lilly CEO David Ricks in a statement. The move in the ...

Shares of Eli Lilly and Co. fell more than 7% in midday ... and U.S. supply across all doses of tirzepatide was available throughout Q4.” The company said the rest of its medications performed ...

Eli Lilly cut its 2024 revenue guidance ... in December reaffirmed its decision to declare the U.S. shortage of tirzepatide — the active ingredient in both drugs — over.